Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931109 · ClinicalTrials.gov registry record
Circulating miRNA in Primary Hyperparathyroidism
A clinical trial of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 96
- Enrollment target
- 1
- Study location
NCT03931109: Completed study of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism, sponsored by University of Pennsylvania.
NCT03931109 is a study of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism that has completed, run by University of Pennsylvania. The registered enrollment target is 96 participants, below the 2,726-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03931109, a study of Osteoporosis, Postmenopausal and Primary Hyperparathyroidism, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone remodeling including biochemical and radiologic studies. 2. To evaluate serum miRNA levels after treatment with parathyroidectomy.
Primary Outcome
Serum miRNA levels
Conditions Studied
Study Locations (1)
Pennsylvania
- Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2024-07-01 |
What the finished NCT03931109 record still lists
NCT03931109 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 2,726-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 0 interventions.
NCT03931109 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03931109 about?
NCT03931109 is a clinical study titled "Circulating miRNA in Primary Hyperparathyroidism". The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone remodeling including biochemical...
What is the current status of trial NCT03931109?
This trial is currently completed. The enrollment target is 96 participants. The study started on 2018-09-07. Estimated completion is 2024-07-01.
What conditions does trial NCT03931109 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal, Primary Hyperparathyroidism.
Who is sponsoring clinical trial NCT03931109?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03931109 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis, Postmenopausal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03931109's enrollment target sits among peer trials
96 6th of 12 higher than 7 of 12 other Osteoporosis, Postmenopausal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis, Postmenopausal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Anabolic Osteoporosis Therapy
RECRUITING · NA
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Comparative Efficacy, Safety, PK, and Immunogenicity Study
ACTIVE NOT RECRUITING · Phase 3
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Romosozumab Use to Build Skeletal Integrity
ACTIVE NOT RECRUITING · Phase 4
-
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI